Concepedia

David Mitcheson

DM

Statistics

Publications

6

Citations

947

H-Index

6

Active since

2012

Affiliations

St. Elizabeth's Medical Center(Current)

Royal Hallamshire Hospital

Astellas Pharma (Netherlands)

Sunnybrook Health Science Centre

Astellas Pharma (United States)

David Mitcheson is an author at St. Elizabeth's Medical Center specializing in medicine, overactive bladder, and overactive bladder management.

Publications per year

2012–2017

6

Publications

6

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology · 2012 · 356 citations

, , +14

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Marcus J. Drake, Christopher R. Chapple, Adil Esen et al. · European Urology · 2016 · 183 citations · Full text

, , +17

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( <scp>SYNERGY</scp> study)

Christopher R. Chapple, Paul Abrams, Salvador Arlandis et al. · British Journal of Urology · 2017 · 174 citations · Full text

, , +17

Urodynamics and Safety of the β <sub>3</sub> -Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Victor W. Νitti, Steven Rosenberg, David Mitcheson et al. · The Journal of Urology · 2013 · 164 citations

, , +17

Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · International Journal of Urology · 2014 · 46 citations · Full text

, , +16

1–5 of 6